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Abstract 
Network approaches are ubiquitous, from social and ecological systems up to complex biological 
processes. In our recently published work we used the network framework for a Systems Medicine 
approach to multiple cancer types, in order to highlight similitudes and differences that can be 
exploited to extend existing therapeutical strategies. These approaches shed new light to 
oncological processes, but allow also to pose “old” questions (like the search for novel drug 
targets) in a “new” way. 
 
Networks and cancer 
In our work “Network integration of multi-tumour omics data suggests novel targeting strategies”1 
we have integrated transcriptional (“phenotype”) and mutational (“genotype”) information from 
11 different types of cancer from “The Cancer Genome Atlas” (TCGA) database2 (Colon and 
Rectum Adenocarcinomas; Lung Adeno- carcinoma, Lung Squamous Cell Carcinoma, Glioblastoma 
Multiforme, Ovarian Serous Cystadenocarcinoma, Breast Invasive Carcinoma, Uterine Corpus 
Endometrial Carcinoma, Brain Lower Grade Glioma, Kidney Renal Clear Cell and Papillary Cell 
Carcinomas) trying to grasp a wider picture of the mechanisms involved in the pathology beyond a 
single-tumour approach. 
We used network methods throughout all our analysis pipeline: to cluster tumours based on 
functional relationship between genes (i.e. generating a “network” of transcriptional profile 
correlations for each tumour) and not based on patients’ similarity; to embed phenotypical and 
genotypical information in a Protein Interaction Network (Bioplex3-Ontocancro4 network), by 
combining high-throughput protein binding experiments3 and biological annotation of known 
cancer-related processes4; prioritizing drug targets based on their role in the constructed 
networks, by identifying the most central nodes (corresponding to genes) in our network5. 
Three tumour clusters were identified, reflecting cancer anatomical proximity (as for kidney and 
intestine carcinomas) but with some interesting difference (e.g. brain tumours not clustering 
together). From each cluster a different network was constructed, starting from the same initial 
Bioplex-Ontocancro “template” network, but with different links depending on cluster-specific 
gene-gene coexpression levels (see Figure 1). From each network, a different set of central genes 
emerged: these signatures were derived from transcriptomics profiles, but were found in 
proximity of known mutated genes, thus evidencing the “interest” of cancer in taking control of 
the underlying biological mechanisms (through mutations) to modify their functionality (via 
transcriptional changes). The expression profile of these signatures also allowed to stratify 
patients inside each cluster (thus independently on their tumour type) in terms of survival, 
showing a clear clinical relevance. Most signature genes were already known as drug targets, or 
were identified as objects of ongoing clinical trials. A comparative analysis of drugs targeting our 
signature genes, against drugs targeting genes in the same networks but not in the signature, was 
performed on more than 300 cell lines from tumours associated to our 11 tumour types6: in many 
cases (>62% in total, >95% in two of the three clusters) the IC50 (i.e. the concentration of a drug 
that gives half-maximal response) was lower for our selected targets. Also a small set of 
experiments was performed in vitro on two cell lines (MCF-7, a breast cancer cell line, and T98G, a 
glioblastoma cell line) showing better response only for signature drug targets.  
This analysis confirmed the validity of our approach for grouping tumours based on a more 
functional and structural (as schematized by the network framework) rather than a merely 
anatomical point of view, and allowed the identification of targets common to all tumours of the 
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same cluster, that could in principle facilitate drug repurposing between these different tumour 
types. 
We obtained some answer, but many more questions can stem from these analyses. We propose 
some of them in the final part of this commentary, with the idea that more information can be 
extracted from the constructed networks, and that further knowledge can be achieved by the 
addition of other types of data to the model. These studies will necessarily require highly 
interdisciplinary efforts, involving clinicians, biologists, statisticians, bioinformaticians and 
mathematical modelling (as provided for example by network theory): 
1) Some of the signature genes had already been identified as drug targets, and thus could be 
directly tested for their efficacy against tumours. What about the other signature genes 
which are not actual drug targets? 
2) We observed a synergistical effect between drugs acting on two signature genes: is synergy 
favoured between neighbouring genes in the Bioplex-Ontocancro network? (similar 
questions are starting to be recently posed, as in ref. 7) 
3) What is the role of epigenetic and post-transcriptional regulation? We remark that DNA 
methylation and miRNA expression are available for most tumours in TCGA, and could thus 
be integrated into the model, or in the same network or as a further layer, in a multiplex 
network fashion8,9 
4) Can we expand our results towards Precision medicine, based on individual mutational and 
transcriptional profile, in order to design individualized therapies with specific drugs taken 
singularly or in combination? 
There is still a long way to a reliable in silico modelling of cancer(s), able to effectively impact 
clinical and pharmacological practice, but undoubtedly the Big Data Era is showing its effects also 
in the biomedical field: the increase in data availability, both in quantity and in data-type variety, 
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Figure 1 caption 
Figure 1. Network of Cluster 2 signature genes (dark blue) and their first neighbours in the BioplexOntocancro network 
(yellow). In the same picture, known mutated genes (light blue) and known drug targets (light green) are shown. The 
red circles highlight six possible gene modules inside the network, that could reflect possible synergistic effects for 
drug targeting or deeper-level biological relationships. 
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